Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
ObjectiveThis study was aimed to evaluate the efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of unresectable hepatocellular carcinoma and to explore a new therapeutic strategy for the treatment of advanced HCC.Patient...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188308/full |
| _version_ | 1797775332526260224 |
|---|---|
| author | Jinpeng Li Mingxin Kong Guangji Yu Song Wang Zhaozhang Shi Huihui Han Yanyan Lin Jutian Shi Jinlong Song |
| author_facet | Jinpeng Li Mingxin Kong Guangji Yu Song Wang Zhaozhang Shi Huihui Han Yanyan Lin Jutian Shi Jinlong Song |
| author_sort | Jinpeng Li |
| collection | DOAJ |
| description | ObjectiveThis study was aimed to evaluate the efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of unresectable hepatocellular carcinoma and to explore a new therapeutic strategy for the treatment of advanced HCC.Patients and methodsA total of 87 patients aged 18-75 years with at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (version 1.1) were included in the study. TACE was administered as needed, and camrelizumab and TKI medication were initiated within two weeks and one week after TACE, respectively. The primary endpoints were progression-free survival and objective response rate.ResultsThe 87 patients in this trial were last evaluated on September 28, 2022, and 35.8% were still receiving treatment at the data cutoff. A total of 34 patients (39.1%) died, and the median OS was not reached. The median PFS was 10.5 months (95% CI: 7.8-13.1). The ORR rate was 71.3% (62/87), and the DCR rate was 89.7% (78/87) per mRECIST. According to RECIST version 1.1, the ORR rate was 35.6% (31/87), and the DCR rate was 87.4% (76/87). Ten patients (11.5%) successfully underwent conversion therapy and all achieved R0 resection. Two patients achieved a complete pathological response, four achieved a major pathological response, and four had a partial response. All treatment-related adverse events were tolerated. No serious adverse events were observed, and no treatment-related deaths occurred.ConclusionsTACE combined with TKI and camrelizumab was safe and effective in treating advanced HCC. Triple therapy may benefit patients with large tumor burden and portal vein cancer thrombus and is expected to provide a new treatment strategy for advanced HCC.Clinical Trial RegistrationClinicalTrials.gov, identifier ChiCTR2000039508 |
| first_indexed | 2024-03-12T22:34:10Z |
| format | Article |
| id | doaj.art-0cbc081f76d84442a0fbe2ca6a46d5ed |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-12T22:34:10Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-0cbc081f76d84442a0fbe2ca6a46d5ed2023-07-21T14:16:39ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-07-011410.3389/fimmu.2023.11883081188308Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinomaJinpeng Li0Mingxin Kong1Guangji Yu2Song Wang3Zhaozhang Shi4Huihui Han5Yanyan Lin6Jutian Shi7Jinlong Song8Intervention Ward One, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaDepartment of Interventional, Weifang People’s Hospital, Weifang, Shandong, ChinaDepartment of Interventional, Linyi Cancer Hospital, Linyi, Shandong, ChinaDepartment of Interventional, Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaDepartment of Oncology, Public Health Clinical Center of Shandong Province, Jinan, Shandong, ChinaDepartment of Medicine, Jiangsu Hengrui Medicine, Shanghai, ChinaDepartment of Medicine, Jiangsu Hengrui Medicine, Shanghai, ChinaIntervention Ward One, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaIntervention Ward One, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaObjectiveThis study was aimed to evaluate the efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of unresectable hepatocellular carcinoma and to explore a new therapeutic strategy for the treatment of advanced HCC.Patients and methodsA total of 87 patients aged 18-75 years with at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (version 1.1) were included in the study. TACE was administered as needed, and camrelizumab and TKI medication were initiated within two weeks and one week after TACE, respectively. The primary endpoints were progression-free survival and objective response rate.ResultsThe 87 patients in this trial were last evaluated on September 28, 2022, and 35.8% were still receiving treatment at the data cutoff. A total of 34 patients (39.1%) died, and the median OS was not reached. The median PFS was 10.5 months (95% CI: 7.8-13.1). The ORR rate was 71.3% (62/87), and the DCR rate was 89.7% (78/87) per mRECIST. According to RECIST version 1.1, the ORR rate was 35.6% (31/87), and the DCR rate was 87.4% (76/87). Ten patients (11.5%) successfully underwent conversion therapy and all achieved R0 resection. Two patients achieved a complete pathological response, four achieved a major pathological response, and four had a partial response. All treatment-related adverse events were tolerated. No serious adverse events were observed, and no treatment-related deaths occurred.ConclusionsTACE combined with TKI and camrelizumab was safe and effective in treating advanced HCC. Triple therapy may benefit patients with large tumor burden and portal vein cancer thrombus and is expected to provide a new treatment strategy for advanced HCC.Clinical Trial RegistrationClinicalTrials.gov, identifier ChiCTR2000039508https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188308/fullcamrelizumabtransarterial chemoembolizationtyrosine kinase inhibitorsunresectable hepatocellular carcinomatherapeutic evaluation |
| spellingShingle | Jinpeng Li Mingxin Kong Guangji Yu Song Wang Zhaozhang Shi Huihui Han Yanyan Lin Jutian Shi Jinlong Song Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma Frontiers in Immunology camrelizumab transarterial chemoembolization tyrosine kinase inhibitors unresectable hepatocellular carcinoma therapeutic evaluation |
| title | Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma |
| title_full | Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma |
| title_fullStr | Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma |
| title_full_unstemmed | Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma |
| title_short | Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma |
| title_sort | safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma |
| topic | camrelizumab transarterial chemoembolization tyrosine kinase inhibitors unresectable hepatocellular carcinoma therapeutic evaluation |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188308/full |
| work_keys_str_mv | AT jinpengli safetyandefficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsandcamrelizumabinthetreatmentofpatientswithadvancedunresectablehepatocellularcarcinoma AT mingxinkong safetyandefficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsandcamrelizumabinthetreatmentofpatientswithadvancedunresectablehepatocellularcarcinoma AT guangjiyu safetyandefficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsandcamrelizumabinthetreatmentofpatientswithadvancedunresectablehepatocellularcarcinoma AT songwang safetyandefficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsandcamrelizumabinthetreatmentofpatientswithadvancedunresectablehepatocellularcarcinoma AT zhaozhangshi safetyandefficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsandcamrelizumabinthetreatmentofpatientswithadvancedunresectablehepatocellularcarcinoma AT huihuihan safetyandefficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsandcamrelizumabinthetreatmentofpatientswithadvancedunresectablehepatocellularcarcinoma AT yanyanlin safetyandefficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsandcamrelizumabinthetreatmentofpatientswithadvancedunresectablehepatocellularcarcinoma AT jutianshi safetyandefficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsandcamrelizumabinthetreatmentofpatientswithadvancedunresectablehepatocellularcarcinoma AT jinlongsong safetyandefficacyoftransarterialchemoembolizationcombinedwithtyrosinekinaseinhibitorsandcamrelizumabinthetreatmentofpatientswithadvancedunresectablehepatocellularcarcinoma |